ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo

Christian Blank, Ian Elliott Brown, Aalok K. Kacha, Mary A. Markiewicz, Thomas F. Gajewski

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

ICAM-1 has been described to provide both adhesion and costimulatory functions during T cell activation. In the setting of antitumor immunity, ICAM-1/LFA-1 interactions could be important at the level of T cell priming by APCs in draining lymph nodes as well as for transendothelial migration and tumor cell recognition at the tumor site. To determine the contribution of ICAM-1 to tumor rejection in vivo, we performed adoptive transfer of 2C TCR-transgenic/RAG2-/- T cells into TCRα-/- vs ICAM-/-/TCRα-/- recipient animals. ICAM-1-deficient mice successfully rejected HTR.C tumors expressing Ld recognized by the 2C TCR, albeit with a kinetic delay. Inasmuch as HTR.C tumor cells themselves express ICAM-1, a second model was pursued using B16-F10 melanoma cells that lack ICAM-1 expression. These cells were transduced to express the SIYRYYGL peptide recognized by the 2C TCR in the context of Kb, which is cross-presented by APCs in H-2b mice in vivo. These tumors also grew more slowly but were eventually rejected by the majority of ICAM-1 -/-/TCRα-/- recipients. Delayed rejection in ICAM-1-/- mice was associated with diminished T cell priming as assessed by ELISPOT. In contrast, T cell penetration into the tumor was comparable in wild-type and ICAM-1-/- hosts, and adoptively transferred primed effector 2C cells rejected normally in ICAM-1-/- recipients. Our results suggest that ICAM-1 contributes to but is not absolutely required for CD8+ T cell-mediated tumor rejection in vivo and dominantly acts at the level of priming rather than the effector phase of the antitumor immune response.

Original languageEnglish (US)
Pages (from-to)3416-3420
Number of pages5
JournalJournal of Immunology
Volume174
Issue number6
StatePublished - Mar 15 2005
Externally publishedYes

Fingerprint

Cross-Priming
Neoplasm Antigens
Intercellular Adhesion Molecule-1
T-Lymphocytes
Neoplasms
Transendothelial and Transepithelial Migration
Enzyme-Linked Immunospot Assay
Lymphocyte Function-Associated Antigen-1
Experimental Melanomas
Adoptive Transfer
Immunity

ASJC Scopus subject areas

  • Immunology

Cite this

ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. / Blank, Christian; Brown, Ian Elliott; Kacha, Aalok K.; Markiewicz, Mary A.; Gajewski, Thomas F.

In: Journal of Immunology, Vol. 174, No. 6, 15.03.2005, p. 3416-3420.

Research output: Contribution to journalArticle

Blank, Christian ; Brown, Ian Elliott ; Kacha, Aalok K. ; Markiewicz, Mary A. ; Gajewski, Thomas F. / ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo. In: Journal of Immunology. 2005 ; Vol. 174, No. 6. pp. 3416-3420.
@article{6a64b8a3215548eab98289b571db6c2f,
title = "ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo",
abstract = "ICAM-1 has been described to provide both adhesion and costimulatory functions during T cell activation. In the setting of antitumor immunity, ICAM-1/LFA-1 interactions could be important at the level of T cell priming by APCs in draining lymph nodes as well as for transendothelial migration and tumor cell recognition at the tumor site. To determine the contribution of ICAM-1 to tumor rejection in vivo, we performed adoptive transfer of 2C TCR-transgenic/RAG2-/- T cells into TCRα-/- vs ICAM-/-/TCRα-/- recipient animals. ICAM-1-deficient mice successfully rejected HTR.C tumors expressing Ld recognized by the 2C TCR, albeit with a kinetic delay. Inasmuch as HTR.C tumor cells themselves express ICAM-1, a second model was pursued using B16-F10 melanoma cells that lack ICAM-1 expression. These cells were transduced to express the SIYRYYGL peptide recognized by the 2C TCR in the context of Kb, which is cross-presented by APCs in H-2b mice in vivo. These tumors also grew more slowly but were eventually rejected by the majority of ICAM-1 -/-/TCRα-/- recipients. Delayed rejection in ICAM-1-/- mice was associated with diminished T cell priming as assessed by ELISPOT. In contrast, T cell penetration into the tumor was comparable in wild-type and ICAM-1-/- hosts, and adoptively transferred primed effector 2C cells rejected normally in ICAM-1-/- recipients. Our results suggest that ICAM-1 contributes to but is not absolutely required for CD8+ T cell-mediated tumor rejection in vivo and dominantly acts at the level of priming rather than the effector phase of the antitumor immune response.",
author = "Christian Blank and Brown, {Ian Elliott} and Kacha, {Aalok K.} and Markiewicz, {Mary A.} and Gajewski, {Thomas F.}",
year = "2005",
month = "3",
day = "15",
language = "English (US)",
volume = "174",
pages = "3416--3420",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "6",

}

TY - JOUR

T1 - ICAM-1 contributes to but is not essential for tumor antigen cross-priming and CD8+ T cell-mediated tumor rejection in vivo

AU - Blank, Christian

AU - Brown, Ian Elliott

AU - Kacha, Aalok K.

AU - Markiewicz, Mary A.

AU - Gajewski, Thomas F.

PY - 2005/3/15

Y1 - 2005/3/15

N2 - ICAM-1 has been described to provide both adhesion and costimulatory functions during T cell activation. In the setting of antitumor immunity, ICAM-1/LFA-1 interactions could be important at the level of T cell priming by APCs in draining lymph nodes as well as for transendothelial migration and tumor cell recognition at the tumor site. To determine the contribution of ICAM-1 to tumor rejection in vivo, we performed adoptive transfer of 2C TCR-transgenic/RAG2-/- T cells into TCRα-/- vs ICAM-/-/TCRα-/- recipient animals. ICAM-1-deficient mice successfully rejected HTR.C tumors expressing Ld recognized by the 2C TCR, albeit with a kinetic delay. Inasmuch as HTR.C tumor cells themselves express ICAM-1, a second model was pursued using B16-F10 melanoma cells that lack ICAM-1 expression. These cells were transduced to express the SIYRYYGL peptide recognized by the 2C TCR in the context of Kb, which is cross-presented by APCs in H-2b mice in vivo. These tumors also grew more slowly but were eventually rejected by the majority of ICAM-1 -/-/TCRα-/- recipients. Delayed rejection in ICAM-1-/- mice was associated with diminished T cell priming as assessed by ELISPOT. In contrast, T cell penetration into the tumor was comparable in wild-type and ICAM-1-/- hosts, and adoptively transferred primed effector 2C cells rejected normally in ICAM-1-/- recipients. Our results suggest that ICAM-1 contributes to but is not absolutely required for CD8+ T cell-mediated tumor rejection in vivo and dominantly acts at the level of priming rather than the effector phase of the antitumor immune response.

AB - ICAM-1 has been described to provide both adhesion and costimulatory functions during T cell activation. In the setting of antitumor immunity, ICAM-1/LFA-1 interactions could be important at the level of T cell priming by APCs in draining lymph nodes as well as for transendothelial migration and tumor cell recognition at the tumor site. To determine the contribution of ICAM-1 to tumor rejection in vivo, we performed adoptive transfer of 2C TCR-transgenic/RAG2-/- T cells into TCRα-/- vs ICAM-/-/TCRα-/- recipient animals. ICAM-1-deficient mice successfully rejected HTR.C tumors expressing Ld recognized by the 2C TCR, albeit with a kinetic delay. Inasmuch as HTR.C tumor cells themselves express ICAM-1, a second model was pursued using B16-F10 melanoma cells that lack ICAM-1 expression. These cells were transduced to express the SIYRYYGL peptide recognized by the 2C TCR in the context of Kb, which is cross-presented by APCs in H-2b mice in vivo. These tumors also grew more slowly but were eventually rejected by the majority of ICAM-1 -/-/TCRα-/- recipients. Delayed rejection in ICAM-1-/- mice was associated with diminished T cell priming as assessed by ELISPOT. In contrast, T cell penetration into the tumor was comparable in wild-type and ICAM-1-/- hosts, and adoptively transferred primed effector 2C cells rejected normally in ICAM-1-/- recipients. Our results suggest that ICAM-1 contributes to but is not absolutely required for CD8+ T cell-mediated tumor rejection in vivo and dominantly acts at the level of priming rather than the effector phase of the antitumor immune response.

UR - http://www.scopus.com/inward/record.url?scp=14844344816&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=14844344816&partnerID=8YFLogxK

M3 - Article

C2 - 15749875

AN - SCOPUS:14844344816

VL - 174

SP - 3416

EP - 3420

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 6

ER -